13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • DCC-2618-03-002

    Acronym: 

    INTRIGUE

    ACTRN/NCT /ethics: 

    NCT03673501

    Scientific title: 

    A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

    Summary of trial and patient characteristics

    Cancer Type Bowel and colon
    Trial Type Treatment
    Phase Phase III Tumour Stream Gastrointestinal Stromal Tumors
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2019-02-11
    Molecular Target Anticipated End Date 2022-03-01
    Cancer Type Bowel and colon
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Gastrointestinal Stromal Tumors
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2019-02-11
    Anticipated End Date 2022-03-01

    Trial Summary

    This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of DCC-2618 to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 358 patients will be randomized in a 1:1 ratio to DCC-2618 150 mg once daily (QD) (continuous dosing for 6 week cycles) or sunitinib 50 mg QD (6 week cycles, 4 weeks on, 2 weeks off).

    Lay Summary

    A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

    Sponsor / Cooperative group

    Deciphera

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Sue Yeend syeend@adelaidecancercentre.com.au 08 8292 2240 Recruiting